can tirzepatide cause elevated liver enzymes Effect of Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Disease and Type 2 Diabetes Mellitus - Arai - 2025 - Hepatology Research Frontiers | Metabolic dysfunction associated

This results in effects secondary to both GLP-1 and GIP receptor activation, such as increased beta cell function and inhibition of glucagon secretion [35]

Moreover, they align institutional practice with the converging recommendations of multiple learned societies and position endoscopy units to navigate the growing influx of GLP-1 RA users without compromising procedural integrity or performance metrics

We explored caregivers willingness to assume treatment risk in exchange for reduced hyperphagia according to a PWS-validated observer-reported outcome measure

Bhunia S, Kolishetti N, Vashist A, Yndart Arias A, Brooks D, Nair M